Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus BYVALSON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus BYVALSON.
ATACAND HCT vs BYVALSON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Valsartan is an angiotensin II receptor blocker (ARB) that selectively binds to the AT1 receptor, inhibiting angiotensin II-mediated vasoconstriction and aldosterone secretion. It also reduces blood pressure and causes vasodilation.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
160 mg orally once daily.
None Documented
None Documented
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Terminal half-life 10-12 hours; allows once-daily dosing; extended in severe renal impairment (up to 20 hours)
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Renal: 60% unchanged; Biliary/Fecal: 40% as metabolites; total clearance ~30 L/h
Category C
Category C
Angiotensin II Receptor Blocker / Thiazide Diuretic
Angiotensin II Receptor Blocker